Selecting and implementing mobile sensors to collect clinical trial endpoint data
Bill Byrom, PhD, Vice President, Product Strategy and Innovation, Signant Health
Jeremy Wyatt, President, ActiGraph
Richard Sutherland, Product Manager, Signant Health
Today, less than 15% of clinical trials capture data from mobile sensors. In many cases these data are used to derive exploratory endpoints, but in some cases they are being used for primary or secondary endpoints.
Mobile sensors collect data that can measure aspects of health and function which are difficult to assess by other means and they enable more frequent assessment outside of the clinic environment. In clinical research, they have the potential to provide deeper insight into intervention effects. However, uncertainty remains in how to select a device that is acceptable to regulators and patients, how to implement mobile sensors appropriately within study protocols, and how to interpret the data they provide.
In this webinar, our experts will discuss these topics with particular reference to activity and sleep monitoring. They will explore current thinking on evidentiary requirements to support mobile sensor selection and clinical endpoint development, as well as approaches to operationalizing the use of mobile sensors that account for the site staff and patient experience.
- Criteria for selecting mobile sensors suitable for clinical trials
- Considerations for deriving validated endpoints that support labeling claims
- Approaches to implementation of mobile sensors in clinical trials
About the Sponsors
The best technology succeeds in the background. Signant Health provides solutions that simplify every step of the patient journey to make it easier for people to participate in, and for sites and study teams to run, clinical trials. Signant unites eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite – an evolution built on more than 20 years of proven clinical research technology. Our intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable hundreds of sponsors and CROs (including all Top 20 pharma) to extend the reach of drug development, expand patient opportunities and improve data quality – helping them bring life-changing therapies to our families and communities around the world.For more information please visit signanthealth.com/.